.
BC Platforms
Predicting COVID-19
BC Platforms, a global leader in clinical and genomic data management, analytics and access, announced that it has joined forces with Japan’s RIKEN research institution and the Finnish Institute for Health and Welfare, in an international research effort to support development of a precision prediction model to identify those most at risk from COVID-19.
RIKEN and THL play significant roles in Japan and Finland, respectively, in the fight against COVID-19, improving society’s resilience to the coronavirus pandemic.
Liver fibrosis test
NHS Tayside has implemented a blood test from Siemens Healthineers to rapidly provide an indication of liver fibrosis severity, enabling prioritisation of clinical treatment for patients at risk of severe liver disease.
The Enhanced Liver Fibrosis test has enabled the Scottish Health Board to reduce the liver clinic waiting list by 43% and more easily route patients to the correct intervention.
The rapid, minimally invasive blood test identifies priority patients.
Oral Fluid Testing
LGC has expanded its innovative portfolio of SARS-CoV-2 quality solutions with its latest release – AccuPlex SARS-CoV-2 in Synthetic Oral Fluid reference material.
The product is designed to support development and testing efforts around novel saliva-based SARS-CoV-2 diagnostics.
It serves as an ideal research tool for assay developers and can also function as a complete quality solution for clinical laboratories employing such tests.
Image Credit | iStock | Shutterstock